Loading...
MET logo

MetLife, Inc.NYSE:MET Rapport sur les actions

Capitalisation boursière US$53.1b
Prix de l'action
US$84.30
US$89.31
5.6% sous-évalué décote intrinsèque
1Y8.6%
7D6.5%
1D
Valeur du portefeuille
Voir

MetLife, Inc.

NYSE:MET Rapport sur les actions

Capitalisation boursière : US$53.1b

MetLife (MET) Aperçu de l'action

MetLife, Inc. est une société de services financiers qui propose des assurances, des rentes, des avantages sociaux et des services de gestion d'actifs dans le monde entier. Plus de détails

MET analyse fondamentale
Score flocon de neige
Évaluation2/6
Croissance future1/6
Performances passées1/6
Santé financière3/6
Dividendes5/6

MET Community Fair Values

Create Narrative

See what 48 others think this stock is worth. Follow their fair value or set your own to get alerts.

MetLife, Inc. Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 MetLife
Historique des cours de bourse
Prix actuel de l'actionUS$84.30
Plus haut sur 52 semainesUS$84.38
Plus bas sur 52 semainesUS$67.33
Bêta0.77
Variation sur 1 mois8.80%
Variation sur 3 mois6.57%
Variation sur 1 an8.55%
Variation sur 3 ans59.75%
Variation sur 5 ans28.39%
Évolution depuis l'introduction en bourse471.53%

Nouvelles et mises à jour récentes

Mise à jour du récit May 03

MET: Share Repurchases And Dividend Increases Will Support Future Upside Potential

Analysts have slightly adjusted their fair value estimate for MetLife, nudging the implied price target from about $89.06 to $89.31. This reflects modest tweaks to assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiples.

Recent updates

Mise à jour du récit May 03

MET: Share Repurchases And Dividend Increases Will Support Future Upside Potential

Analysts have slightly adjusted their fair value estimate for MetLife, nudging the implied price target from about $89.06 to $89.31. This reflects modest tweaks to assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiples.
Seeking Alpha Apr 26

MetLife: A Great Time To Buy The Preferred Stock

Summary MetLife preferred shares now yield over 6% as rising rates pressure prices, offering attractive risk/reward for long-term investors. MET's preferred dividends are well covered, with payout ratios under 4% of adjusted earnings and likely dropping to 3% as EPS grows. Series F preferred, MET.PR.F, trades at ~$19.25 for a 6.15% yield. Low payout ratio and strong balance sheet support continued payments. Double-digit adjusted EPS growth and 15–17% ROE guidance suggest MET common shares also offer compelling upside below $80/share. Read the full article on Seeking Alpha
Mise à jour du récit Apr 17

MET: Share Repurchases Following Index Exit Will Support Future Upside Potential

Analysts have slightly reduced their MetLife fair value estimate to $89.06 from $90.50, reflecting minor adjustments to assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio that refine their outlook for the shares. What's in the News MetLife has been dropped from the S&P 100 index, which may influence how some index funds and benchmarks gain exposure to the stock (Key Developments).
Mise à jour du récit Apr 01

MET: Share Repurchases And Index Exit Will Shape Future Upside Potential

Analysts have trimmed their average MetLife price target slightly to $90.50 from $90.73, citing updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News MetLife, Inc.
Mise à jour du récit Mar 18

MET: Share Repurchases Will Support Future Upside Potential

Analysts have slightly adjusted their price target for MetLife to $90.73 from $90.93, reflecting updated views on discount rates, revenue growth, profit margins, and future price-to-earnings (P/E) assumptions. What's in the News MetLife reported that from October 1, 2025 to January 31, 2026 it repurchased 7,608,263 shares, representing 1.15% of shares, for a total of US$600 million under its current buyback program (Key Developments).
Mise à jour du récit Mar 04

MET: Buybacks And Retirement Income Agreements Will Drive Future Upside

Analysts have trimmed their price target on MetLife to about $90.93 from roughly $92.93. This reflects updated views on slightly lower expected revenue growth, a modestly softer profit margin, a higher discount rate, and a largely unchanged future P/E assumption.
Mise à jour du récit Dec 16

MET: Retirement Income Agreements Will Drive Future Upside In Earnings Power

Analysts have marginally reduced their price target on MetLife to approximately 92.93 dollars from 93 dollars, citing a slightly higher assumed discount rate. This more than offsets modest improvements in forecast profit margins and valuation multiples.
Mise à jour du récit Nov 07

MET: Revenue Will Advance On New Retirement Income And Employee Support Agreements

Analysts have slightly reduced their price target for MetLife from $93.33 to $93.00, reflecting minor adjustments to discount rate and profit margin assumptions. They maintain a positive outlook on revenue growth.
Mise à jour du récit Oct 24

Digital Expansion And Employee Support Benefits Will Drive Outperformance Ahead

Analysts have modestly raised their price target for MetLife, increasing it from $93.00 to $93.33 per share. They cited slight improvements in projected revenue growth and profit margins as the reason for the adjustment.
Mise à jour du récit Oct 09

International Demand And Digital Transformation Will Fuel Success

Analysts have raised their fair value estimate for MetLife from $91.86 to $93.00. This reflects slight adjustments to discount rates and growth assumptions.
Mise à jour du récit Sep 04

International Demand And Digital Transformation Will Fuel Success

With no change in revenue growth forecasts or discount rate, MetLife’s fair value estimate remains steady at $91.86. What's in the News MetLife will redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, at $1,000 per share; dividends of $19.250 per share will be paid separately, and all further dividends cease post-redemption.
Article d’analyse Jun 11

It's Unlikely That MetLife, Inc.'s (NYSE:MET) CEO Will See A Huge Pay Rise This Year

Key Insights MetLife's Annual General Meeting to take place on 17th of June Salary of US$1.50m is part of CEO Michel...
Seeking Alpha Feb 11

MetLife: Double-Digit EPS Growth With A Single-Digit P/E, Strong Chart

Summary MetLife, Inc. is rated a buy due to its solid value, above-market dividend yield, and favorable technical chart despite recent earnings misses. Insurance stocks, including MET, have lagged behind the Financials sector and S&P 500, with premium increases expected to slow as consumers react to rising costs. MET's 2025 outlook is positive, with analysts forecasting over 17% EPS growth and 5%-6% revenue growth, despite recent underperformance in certain segments. Key risks include lower stock prices, falling interest rates, and regulatory challenges, but MET's strong investment income and share buybacks are positive factors. Read the full article on Seeking Alpha
Seeking Alpha Nov 26

MetLife Upgraded To Buy As Financials And Insurance Show Further Upside Potential

Summary MetLife stock gets upgraded to a buy, from my prior hold rating, as indicators point to further share price potential in the financials sector, as well as the insurance subsector. Data points to future continued demand for annuities and life insurance, and MetLife has in Q3 achieved new organic customer growth in 2 key businesses. Although its dividend yield is not stellar vs. peers, it has a 10-year track record of proven dividend growth, something it has potential to continue. Even though it is trading at a 10-year high, it remains undervalued on P/E and EV/EBITDA vs. peers, so continues to present a buy opportunity. Read the full article on Seeking Alpha
Seeking Alpha Sep 23

MetLife: One Of The Best Life Insurance Stocks

Summary MetLife's strong financial performance, with a 17.5% increase in adjusted EPS and a 15.2% rise in book value, makes it an attractive investment. Despite comparable performance to Aflac, MetLife's lower valuation offers better value for shareholders. MetLife's growing dividend yield and robust share buyback program enhance shareholder value, with ample cash reserves supporting future buybacks. Risks include potential commercial real estate portfolio defaults and market volatility, but MetLife's strong fundamentals and attractive valuation make it a compelling choice. Read the full article on Seeking Alpha
Seeking Alpha Jul 09

Higher For Longer? Consider MetLife's Preferred Shares With A 6.6% Yield

Summary MetLife's preferred shares, particularly the Series A with floating dividends, offer potential for investors in a 'higher for longer' inflation and interest rate environment. MetLife's strong financial performance in Q1 2021, with net profit covering preferred dividends by less than 8%. Series A preferred shares have a minimum 4% floor for dividends, with potential for higher yields based on 3 month SOFR rate adjustments. Read the full article on Seeking Alpha
Seeking Alpha Jun 26

MetLife Looks Like An Undervalued Property In An Unpopular Neighborhood

Summary MetLife shares have outperformed peers, but life insurance stocks have not really been in favor given concerns about CRE losses and rate cuts. Higher rates have allowed MetLife to reprice its investment portfolio at higher rates and sell more spread products, and the benefits will last even as rates fall. There are understandable concerns about MetLife's CRE exposure (office in particular), as the insurer is overweight here, but losses will take years to materialize and can be absorbed. MetLife's focus on profitable core businesses like group life and health, pension risk transfer, and international markets should lead to steady growth and returns for investors. This is something of a contrarian call given weak sector sentiment, but MetLife's differentiated model and ability to out-earn its cost of equity should drive outperformance. Read the full article on Seeking Alpha
Seeking Alpha Apr 18

MetLife: Healthy But Lacks Clear Advantages

Summary MetLife has experienced a decade of light shrinking instead of growth. This started as early as 2015 and was attributed to increased competition and a decrease in annuity sales, but this never seemed to improve. With their current size, competitive hurdles, and lack of clear targets for growth internationally, shares of MET will likely only give mediocre returns at best. Read the full article on Seeking Alpha

Rendement pour les actionnaires

METUS InsuranceUS Marché
7D6.5%2.5%-0.8%
1Y8.6%-6.1%27.1%

Rendement vs Industrie: MET a dépassé le secteur US Insurance qui a rapporté -6.1 % au cours de l'année écoulée.

Rendement vs marché: MET a sous-performé le marché US qui a rapporté 27.1 % au cours de l'année écoulée.

Volatilité des prix

Is MET's price volatile compared to industry and market?
MET volatility
MET Average Weekly Movement3.6%
Insurance Industry Average Movement4.3%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Cours de l'action stable: MET n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de MET ( 4% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
199946,000Michel Khalafwww.metlife.com

MetLife, Inc. est une société de services financiers qui propose des assurances, des rentes, des avantages sociaux et des services de gestion d'actifs dans le monde entier. Elle exerce ses activités dans six secteurs : Avantages collectifs ; Solutions de retraite et de revenu ; Asie ; Amérique latine ; Europe, Moyen-Orient et Afrique ; et MetLife Holdings. La société propose des assurances vie, dentaire, invalidité collective de courte et de longue durée, congés familiaux et médicaux payés, invalidité individuelle, décès et mutilation accidentels, accident et santé, vision et animaux de compagnie, ainsi que des plans juridiques prépayés ; des accords de services administratifs réservés aux employeurs ; et des contrats généraux et séparés, et des contrats synthétiques à intérêt garanti, ainsi que des accords de financement privé à taux variable.

MetLife, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de MetLife se comparent-ils à sa capitalisation boursière ?
MET statistiques fondamentales
Capitalisation boursièreUS$53.09b
Bénéfices(TTM)US$3.43b
Recettes(TTM)US$77.58b
15.8x
Ratio P/E
0.7x
Ratio P/S

Le site MET est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
MET compte de résultat (TTM)
RecettesUS$77.58b
Coût des recettesUS$59.15b
Marge bruteUS$18.43b
Autres dépensesUS$15.00b
Les revenusUS$3.43b

Derniers bénéfices déclarés

Mar 31, 2026

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)5.34
Marge brute23.75%
Marge bénéficiaire nette4.43%
Ratio dettes/capitaux propres178.0%

Quelles ont été les performances à long terme de MET?

Voir les performances historiques et les comparaisons

Dividendes

2.7%
Rendement actuel des dividendes
44%
Ratio de distribution

Le site MET verse-t-il des dividendes fiables ?

Voir MET l'historique des dividendes et les indices de référence
Quand faut-il acheter MET pour recevoir un dividende à venir ?
MetLife dates des dividendes
Date ex-dividendeMay 12 2026
Date de paiement du dividendeJun 09 2026
Jours jusqu'au dividende Ex10 days
Jours jusqu'à la date de paiement du dividende18 days

Le site MET verse-t-il des dividendes fiables ?

Voir MET l'historique des dividendes et les indices de référence

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/21 07:25
Cours de l'action en fin de journée2026/05/21 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

MetLife, Inc. est couverte par 32 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Jacob KilsteinArgus Research Company
Jay GelbBarclays
Taylor ScottBarclays